Center for Preventive Medicine, Keio University Hospital, Tokyo, Japan.
Center for Preventive Medicine, Keio University Hospital, Tokyo, Japan.
Clin Nutr ESPEN. 2020 Aug;38:86-93. doi: 10.1016/j.clnesp.2020.05.025. Epub 2020 Jun 20.
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is significantly related to sarcopenia as well as obesity and its associated comorbidities. This cross-sectional study aims to examine the association between four body composition phenotypes (standard, obesity alone, sarcopenia alone, sarcopenic obesity) and non-obese NAFLD, or obese NAFLD.
Reduced muscle mass and high percentage of body fat mass was measured by dual-energy x-ray absorptiometry, and body composition phenotypes were determined, according to Asian criteria for sarcopenia. Based on body mass index (BMI) cut-off point (25 kg/m) and hepatic steatosis on ultrasound, 748 subjects who underwent a health checkup were enrolled and divided into three groups: non-obese NAFLD, obese NAFLD, and no steatosis.
Of 563 subjects (64.1 ± 13.0 years) without secondary causes for steatosis, the overall prevalence of non-obese NAFLD and obese NAFLD were 17% and 16%, respectively. The former prevalence remained relatively constant at around 20% from the 50s to 80's, while the proportion of sarcopenic obesity in all subjects increased gradually with age, reaching 18% in the 80's. Multivariate analysis demonstrated a significant association between sarcopenic obesity and non-obese NAFLD after adjusting for confounders (odds ratio = 2.367, 95% confidence interval = 1.317-4.254, P = 0.004). On the other hand, no significant association was found between obesity alone and obese NAFLD, when BMI and visceral adipose tissue were added as confounders, although 91% of obese NAFLD was included in obesity alone phenotype.
Non-obese NAFLD had a significant association with sarcopenic obesity, independent of metabolic confounders. Early treatment intervention for non-obese NAFLD could suppress the deterioration of sarcopenic obesity because non-obese NAFLD might be a risk factor for sarcopenic obesity.
非酒精性脂肪性肝病(NAFLD)与肌肉减少症以及肥胖及其相关合并症密切相关。本横断面研究旨在探讨四种身体成分表型(标准型、单纯肥胖型、单纯肌肉减少型、肌肉减少性肥胖型)与非肥胖型 NAFLD 或肥胖型 NAFLD 的关系。
通过双能 X 射线吸收法测量肌肉减少和体脂肪百分比高,根据亚洲肌肉减少症标准确定身体成分表型。根据体质指数(BMI)切点(25kg/m)和超声肝脂肪变性,对接受健康检查的 748 名受试者进行分组,分为三组:非肥胖型 NAFLD、肥胖型 NAFLD 和无脂肪变性。
在 563 名(64.1±13.0 岁)无继发性脂肪变性的受试者中,非肥胖型 NAFLD 和肥胖型 NAFLD 的总患病率分别为 17%和 16%。前者的患病率在 50 多岁到 80 多岁之间相对稳定在 20%左右,而所有受试者中肌肉减少性肥胖的比例随着年龄的增长逐渐增加,在 80 多岁时达到 18%。多变量分析显示,在校正混杂因素后,肌肉减少性肥胖与非肥胖型 NAFLD 之间存在显著关联(比值比=2.367,95%置信区间=1.317-4.254,P=0.004)。另一方面,当将 BMI 和内脏脂肪组织作为混杂因素添加进去后,单纯肥胖与肥胖型 NAFLD 之间没有显著关联,尽管肥胖型 NAFLD 中有 91%归入单纯肥胖表型。
非肥胖型 NAFLD 与肌肉减少性肥胖显著相关,与代谢混杂因素无关。早期对非肥胖型 NAFLD 的治疗干预可能会抑制肌肉减少性肥胖的恶化,因为非肥胖型 NAFLD 可能是肌肉减少性肥胖的一个危险因素。